| Autoantibodies against type I IFNs in patients with life-threatening COVID-19 P Bastard, LB Rosen, Q Zhang, E Michailidis, HH Hoffmann, Y Zhang, ... Science 370 (6515), eabd4585, 2020 | 2527 | 2020 |
| Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Q Zhang, P Bastard, Z Liu Science 370 (6515), 2020 | 2186 | 2020 |
| The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology W Mullens, K Damman, VP Harjola, A Mebazaa, HP Brunner‐La Rocca, ... European journal of heart failure 21 (2), 137-155, 2019 | 908 | 2019 |
| Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure A Ortiz, A Covic, D Fliser, D Fouque, D Goldsmith, M Kanbay, F Mallamaci, ... The lancet 383 (9931), 1831-1843, 2014 | 513 | 2014 |
| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 466 | 2021 |
| Galectin-3 mediates aldosterone-induced vascular fibrosis L Calvier, M Miana, P Reboul, V Cachofeiro, E Martinez-Martinez, ... Arteriosclerosis, thrombosis, and vascular biology 33 (1), 67-75, 2013 | 466 | 2013 |
| Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms V Fontaine, MP Jacob, X Houard, P Rossignol, D Plissonnier, ... The American journal of pathology 161 (5), 1701-1710, 2002 | 416 | 2002 |
| The systemic nature of CKD C Zoccali, R Vanholder, ZA Massy, A Ortiz, P Sarafidis, FW Dekker, ... Nature Reviews Nephrology 13 (6), 344-358, 2017 | 405 | 2017 |
| Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints A Kearney-Schwartz, P Rossignol, S Bracard, J Felblinger, R Fay, ... Stroke 40 (4), 1229-1236, 2009 | 401 | 2009 |
| Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction B Levy, R Clere-Jehl, A Legras, T Morichau-Beauchant, M Leone, ... Journal of the American College of Cardiology 72 (2), 173-182, 2018 | 390 | 2018 |
| Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference CM Clase, JJ Carrero, DH Ellison, ME Grams, BR Hemmelgarn, ... Kidney international 97 (1), 42-61, 2020 | 373 | 2020 |
| X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19 T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ... Science immunology 6 (62), eabl4348, 2021 | 344 | 2021 |
| Heart failure drug treatment P Rossignol, AF Hernandez, SD Solomon, F Zannad The Lancet 393 (10175), 1034-1044, 2019 | 342 | 2019 |
| Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: the PARTAGE study A Benetos, C Labat, P Rossignol, R Fay, Y Rolland, F Valbusa, P Salvi, ... JAMA internal medicine 175 (6), 989-995, 2015 | 330 | 2015 |
| Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference AA House, C Wanner, MJ Sarnak, IL Piña, CW McIntyre, P Komenda, ... Kidney international 95 (6), 1304-1317, 2019 | 327 | 2019 |
| Extracellular Cardiac Matrix Biomarkers in Patients With Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure: Insights From the Eplerenone … W Iraqi, P Rossignol, M Angioi, R Fay, J Nuée, JM Ketelslegers, J Vincent, ... Circulation 119 (18), 2471-2479, 2009 | 323 | 2009 |
| Evaluation of kidney function throughout the heart failure trajectory–a position statement from the Heart Failure Association of the European Society of Cardiology W Mullens, K Damman, JM Testani, P Martens, C Mueller, J Lassus, ... European journal of heart failure 22 (4), 584-603, 2020 | 318 | 2020 |
| Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo … R Agarwal, P Rossignol, A Romero, D Garza, MR Mayo, S Warren, J Ma, ... The Lancet 394 (10208), 1540-1550, 2019 | 299 | 2019 |
| Cardiorenal syndrome revisited F Zannad, P Rossignol Circulation 138 (9), 929-944, 2018 | 295 | 2018 |
| Association of galectin‐3 and fibrosis markers with long‐term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights … N Lopez‐Andrès, P Rossignol, W Iraqi, R Fay, J Nuée, S Ghio, ... European journal of heart failure 14 (1), 74-81, 2012 | 288 | 2012 |
